HUMORAL REJECTION IN THE GENESIS OF OBSTETRIC PATHOLOGY


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The term «fetal allograft» reflects the immunological status of fetal tissues in the maternal organism. Impaired tolerance formation processes lead to the development of pregnancy pathology, which are characterized by activation of the cellular and humoral components of the immune system with the development of clinical manifestations of varying rejection. It is suggested that there are parallels between acute graft rejection and fetal rejection in miscarriage, as well as between chronic rejection and preeclampsia. Today the cellular mechanisms of allogeneic or semi-allogeneic graft rejection are better known than the humoral ones. However, all types of rejection are shown to occur with the antibodies of different nature being involved. The purpose of this review is to analyze updates on the role of humoral rejection in the pathogenesis of pregnancy pathology.

Texto integral

Acesso é fechado

Sobre autores

M. ZIGANSHINA

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: mmz@mail.ru

S. PAVLOVICH

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: st.pavlovich@mail.ru

N. BOVIN

M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences

Email: professorbovin@yandex.ru

G. SUKHIKH

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: gtsukhikh@mail.ru

Bibliografia

  1. Carter A.M. Comparative studies of placentation and immunology in non-human primates suggest a scenario for the evolution of deep throphoblast invasion and an rxplanation for human pregnancy disorders. Reproduction. 2011;141(4): 391-6.
  2. Guleria I., Sayegh M.H. Maternal acceptance of the fetus: true human tolerance. J. Immunol. 2007; 178(4): 3345-51.
  3. Laresgoiti-Servitje E., Gomez-Lopez N, Olson D.M. An immunological insight into the origins of pre-eclampsia. Hum. Reprod. Update. 2010; 16(5): 510-24.
  4. Ercilla M.G., Martorell J. Immunological study of the donor-recipient pair. Nefrologia. 2010; 30(Suppl.2): S60-70.
  5. Uchida J., Machida Y., Iwai T, Naquanuma T., Kitamoto K., Iquchi T. et al. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titre kidney transplantation. Transplant. Proc. 2010; 42(10): 3998-4002.
  6. Samsami Dehaghani A., Doroudchi M., Kalantari T., Pezeshki A.M., Ghaderi A. Heterozygosity in CTLA-4 gene and severe preeclampsia. Int. J. Gynecol. Obstet. 2005; 88(1): 19-24.
  7. Lee J., Romero R., Dong Z., Xu Y., Qureshi F., Jacques S. et al. Unexplained fetal death has a biological signature of maternal anti-fetal rejection: chronic chorioamnionitis and alloimmune anti-human leucocyte antigen antibodies. Histopathology. 2011; 59(5): 928-38.
  8. Wilczynski J.R. Immunological analogy between allograft rejection, recurrent abortion and pre-eclampsia. Hum. Immunol. 2006; 67(7): 492 -511.
  9. Rossini A.A., Greiner D.L., Mordes J.P. Induction of immunologic tolerance for transplantation. Physiol. Rev. 1999; 79(1): 99-110.
  10. Sumitran-Holgersson S. HLA-specific alloantibodies and renal graft outcome. Nephrol. Dial.Transplant. 2001; 16(5): 897-904.
  11. Lietz K., John R., Burke E., Schuster M., Roqers T.B., Suciu-Foca N. et al. Immunoglobulin M-to-Immunoglobulin G anti-human leukocyte antigen class ІІ antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease culprit. Circulation. 2005; 112(6): 2468-76.
  12. Tinckam K.J., Chandraker A. Mechanisms and role of HLA and non-HLA alloantibodies. Clin. J. Am. Soc. Nephrol. 2006; 1(3): 404-14.
  13. Bohmig G.A., Exner M., Habicht A., Schillinger M., Lang U., Kletzmayr J. et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J. Am. Soc. Nephrol. 2002; 13(4): 1091-9.
  14. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J. Am. Soc. Nephrol. 2007; 18(4): 1046-56.
  15. Bartel G., Walch K., Wahrmann M., Plis S.,KusselL., PolteranesS. et al. Prevalence and qualitative properties of circulating antihuman leukocyte antigen alloantibodies after pregnancy: no association with unexplained recurrent miscarriage. Hum. Immunol. 2011; 72(2): 187-92.
  16. Lee J., Romero R., Xu Y., Kim J.S., Topping V., Yoo W. et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One. 2011; 6(2): e16806.
  17. Regan L., Braude P.R., Hill D.P. A prospective study of the incidence, time of appearance of anti-paternal lymphocytotoxic antibodies in human pregnancy. Hum. Reprod. 1991; 6(2): 294-8.
  18. Nielsen H.S., Witvliet M.D., Steffensen R., Haasnoot G.W., Goulmy E., Christiansen O.B. et al. The presence of HLA-antibodies in recurrent miscarriage patients is associated with a reduced chance of a live birth. J. Reprod. Immunol. 2010; 87(1-2): 67-73.
  19. Lee J., Romero R., Xu Y., Kim J.S., Park J.Y., Kusanovic J.P. et al. Maternal HLA panel-reactive antibodies in early gestation positively correlate with chronic chorioamnionitis: evidence in support of the chronic nature of maternal anti-fetal rejection. Am. J. Reprod. Immunol. 2011; 66(6): 510-26.
  20. Kim M.J., Romero R., Kim C.J., Tarca A.L., Chhauy S., LaJeunesse C. et al. Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-marernal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal craft-versus-host disease. J. Immunol. 2009; 182(6): 3919-27.
  21. Kim J.S., Romero R., Kim M.R., Kim Y.M., Friel L., Espinosa J., Kim C.J. Involvement of Hofbauer cells and maternal T cells in villitis of unknown aetiology. Histopathology. 2008; 52(4): 457-64.
  22. Labarrere C.A., Faulk W.P. Maternal cells in chorionic villi from placentae of normal and abnormal human pregnancies. Am. J. Reprod. Immunol.1995; 33(1): 54-9.
  23. Redline R.W., Patterson P. Villitis of unknown etiology is associated with major infiltration of fetal tissue by maternal inflammatory cells. Am. J. Pathol. 1993; 143(2): 473-79.
  24. Cohen F., Zuelzer W.W., Gustafson D.C., Evans M.M. Mechanisms of isoimmunization. I. The transplacental passage of fetal erythrocytes in homospecific pregnancies. Blood. 1964; 23: 621-46.
  25. Sebring E.S., Polesky H.F. Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effects. Transfusion. 1990; 30(4): 344-57.
  26. Holt S., Donaldson H., Hazlehurst G., Varghese Z., Contreras M., Kingdon E. et al. Acute transplant rejection induced by blood transfusion reaction to the Kidd blood group system. Nephrol. Dial.Transplant. 2004;19(9): 2403-6.
  27. Tasaki M., Nakajima T., Imai N., Nakagawa Y., Saito K., Takahashi K. et al. Detection of allogeneic blood group A and B enzyme activities in patients with ABO incompatible kidney transplantation. Glycobiology. 2010; 20(10): 1251-8.
  28. Warner P.R., Nester T.A. ABO-incompatible solid-organ transplantation culprit. Am. J. Clin. Pathol. 2006; 125(Suppl.): S87-94.
  29. Dahlseide A.L. Succcessful ABO incompatible organ transplantation. Univ. Alberta Health Sci. J. 2005; 2(1): 17-20.
  30. Eastlund T. The histo-blood group ABO system and tissue transplantation.Transfusion.1998; 38(10): 975-88.
  31. Garratty G., Telen M.J., Petz L.D. Red cell antigens as functional molecules and obstacles to transfusion. Hematology Am. Soc. Hematol. Educ. Program. 2002; 445-62.
  32. Spalter S.H., Kaveri S.V., Bonnin E., Mani J.C., Carltron J.P, Kazatchkine M.D. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood. 1999; 93(12): 4418-24.
  33. Готье С.В., Цирульникова О.М., Аммосов А.А., Лурье Ю.Э., Мойсюк Я.Г., Попцов В.Н. и др. Опыт АВО-несовместимых трансплантаций печени. Вестник трансплантологии и искусственных органов. 2011; 13(2): 21-8.
  34. Anstee D.J. The relationship between blood groups and disease. Blood. 2010; 115(23): 4635-43.
  35. Ghasemi N., Sheikhha M.H., Davar R., Soleimanian S. ABO bloods group incompatibility in recurrent abortion. Iran. J. Pediatr. Hematol. Oncol. 2011; 29(1): 62-6.
  36. Saldanha S.G., Costa A.R. Genetic counseling in two cases of possible ABO incompatibility. Rev. Brasil. Genet. 1979; 2(3): 191-8.
  37. Lurie S., Ben-Aroya Z., Eldar S., Sadan O. Association of Lewis blood group phenotype with preterm premature rupture of membranes. J. Soc. Gynecol. Investig. 2003;10(5): 291-93.
  38. Hudson K.E., Lin E., Hendrickson J.E. Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood. 2010;115(19): 3989-96.
  39. Morales-Buenrostro L.E., Terasaki P.I., Marino-Vazquez L.A., Lee J.H., El-Awar N., Alberu J. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008; 86(8): 1111-15.
  40. Pozsonyi E., Gyorgy B., Berki T., Banlaki Z., Buzas E., Rajczy K. et al. HLA-association of serum levels of natural antibodies. Mol. Immunol. 2009; 46(7): 1416-23.
  41. Xia Y., Kellems R.E. Is preeclampsia an autoimmune disease? Clin. Immunol. 2009; 133(1): 1-12.
  42. Dragun D. Agonistic antibody-triggered stimulation of angiotensin ІІ type 1 receptor and renal allograft vascular pathology. Nephrol. Dial. Transplant. 2007; 22(7): 1819-22.
  43. Xia Y., Ramin S.M., Kellems R.E. Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia. Hypertension. 2007; 50(2): 269-75.
  44. Dechend R., Gratze P., Wallukat G., Shagdarsuren E., Plehm R., Brasen J.H. et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension. 2005; 45(4): 742-46.
  45. LaMarca B., Parrish M., Fournier L., Murphy S.R., Roberts L., Glover P. et al. Hypertension in response to autoantibodies to the angiotensin ІІ type 1 receptor (AT1-AA) in pregnant rats. Hypertension. 2009; 54(4): 905-9.
  46. Walther T., Wallukat G., Jank A., Bartel S., Schultheiss H.P., Faber R. et al. Angiotensin ІІ type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005; 46(6): 1275-79.
  47. Hubel C.A., Wallukat G., Wolf M., Herse F., Rajakumar A., Roberts J.M. et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia. Hypertension. 2007;49(3): 612-17.
  48. Xia Y., Zhou C.C., Ramin S.M., Kellems R.E. Angiotensin receptors, autoimmunity, andpreeclampsia. J. Immunol. 2007; 179(6): 3391-95.
  49. Fitzgerald B., Shannon P., Kingdom J., Keating S. Rounded intraplacental haematomas due to decidual vasculopathy have a distinctive morphology. J. Clin. Pathol. 2011; 64(8): 729-32.
  50. Wehner J., Morrell C.N., Reynolds T., Rodriguez E.R., Baldwin W.M. 3rd. Antibody and complement in transplant vasculopathy. Circ. Res. 2007;100(2): 191-203.
  51. Черний В.И., Чурилов А.В., Кабанько Т.П., Балацко В.С., Агафонов Ю.Н. Антифосфолипидный синдром. Этиология, патогенез, диагностика, лечение и профилактика. Медицинские неотложные состояния. 2007; 10(3): 13-8.
  52. Keswani S.C., Chauhan N. Antiphospholipid syndrome. J. Roy. Soc. Med. 2002; 95(7): 336-41.
  53. Lim W., Growther M.A., Eikelboom J.W. Management of antiphospholipid antibody syndrome. JAMA. 2006; 295(9): 1050-57.
  54. Rand J.H. Molecular pathogenesis of the antiphospholipid syndrome. Circ. Res. 2002; 90(1): 29-37.
  55. Аржанова О.Н., Шляхтенко Т.Н., Сельков С.А. Роль антифосфолипидных антител (АФА) в патогенезе невынашивания беременности. Журнал акушерства и женских болезней. 2002; 50(2): 18-23.
  56. Макацария А.Д., Шаховская Е.Н. Профилакика повторных репродуктивных потерь при антифосфолипидном синдроме. Врач. 2008;10: 89-91.
  57. Сухих Г.Т., Менжинская И.В., Ванько Л.В., Кирющенков П.А., Сидельникова В.М., Петрунин Д.Д. Антитела к фосфолипидам и β2-гликопротеину-I у беременных с плацентарной недостаточностью и задержкой внутриутробного развития плода. Проблемы беременности. 2004; 9: 37-40.
  58. Rai R. Obstetric management of antiphospholipid syndrome. J. Autoimmun. 2000; 15(2): 203-7.
  59. Cervera R. European forum on antiphospholipid antibodies: brief history report and governance document. Lupus. 2012; 21(7): 699-703.
  60. Devreese K., Hoylaerts M.F. Challenges in the diagnosis of the antiphospholipid syndrome. Clin. Chem. 2010; 56(6): 930-40.
  61. Nunez-Alvarez C.A., Cabiedes J. Pathogenic mechanisms of the anti-phospholipid antibodies. Reumatol. Clin. 2011; 7(1): 72-6.
  62. Hughes G.R., Khamashta M.A. Seronegative antiphospholipid syndrome. Ann. Rheum. Dis. 2003; 62(12): 1127.
  63. Miret C., Cervera R., Reverter J.C., Garcia-Carrasco M., Ramos M. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient “seronegative” antiphospholipid syndrome. Clin. Exp. Rheumatol. 1997; 15: 541-4.
  64. Ortona E., Capozzi A., Colasanti T., Conti F., Alessandri C., Longo A. et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010; 116(16): 2960-67.
  65. Castaneda Ospina S.A., Cardona Maya W.D., Bueno Sanchez J.C., Cadavid Jaramillo A.P. Pregnancy outcome in women with antiphospholipid syndrome and alloimmunity: a case report. Sao Paulo Med. J. 2003; 121(6): 248-50.
  66. Thi Thuong D.L., Tieulie N., Costedoat N., Andreu M.R., Wechsler B., Vauthier-Brouzes D. et al. The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann. Rheum. Dis. 2005; 64(2): 273-78.
  67. Ritis K., Doumas M., Mastellos D., Micheli A., Giaglis S., Magotti P. et al. A novel C5a receptor-tissue factor cross-talk in neutrophilis links innate immunity to coagulation pathways. J. Immunol. 2006;177(7): 4794-801.
  68. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N. et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood. 2007; 110(7): 2423-31.
  69. Bokarewa M.I., Morrissey J.H., Tarkowsky A. Tissue factor as a proinflammatory agent. Arthr. Res. 2002; 4(3): 190-5.
  70. Matsuyama M., Yoshimura R., Akioka K., Okamoto M., Ushigome H., Kadotani Y. et al. Tissue factor antisense oligonucleotides prevent renal ischemia-reperfusion injury. Transplantation. 2003; 76(5): 786-91.
  71. Praprotnik S., Blank M., Levy Y., Tavor S., Boffa M.C., Weksler B. et al. Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int. Immunol. 2001;13(2): 203-10.
  72. Varela C., de Haro J., Bleda S., Esparza L., de Maturana I.L., Acin F. Anti-endothelial cell antibodies are associated with peripheral arterial disease and markers of endothelial dysfunction and inflammation. Interact. Cardiovasc. Thorac. Surg. 2011; 13(5): 463-7.
  73. King A., Boocock C., Sharkey A.M., Gardner L., Beretta A., Siccardi A.G. et al. Evidence for the expression of HLA-C class I mRNA and protein by human first trimester trophoblast. J. Immunol. 1996; 156(6): 2068-76.
  74. Meroni P., Ronda N., Raschi E., Borghi M.O. Humoral autoimmunity against endothelium: theory or reality? Trends Immunol. 2005; 25(5): 275-81.
  75. Jordan S.C., Yap H.K., Sakai R.S., Alfonso P., Fitchman M. Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation.1988; 46(4): 585-87.
  76. Rose M.L. Role of MHC and non-MHC alloantibodies in graft rejection. Curr. Opin. Organ Transplant. 2004; 9:16-22.
  77. Sun Q., Liu Z., Chen J., Chen H., Wen J., Cheng D. et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin. J. Am. Soc. Nephrol. 2008; 3(5): 1479-86.
  78. Sun Q., Cheng Z., Cheng D., Chen J., Ji S., Wen J. et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int. 2011; 79(6): 655-62.
  79. Yamamoto T., Geshi Y., Kuno S. Kase N., Mori H. Anti-endothelial cell antibody in preeclampsia: clinical findings and serum cytotoxicity to endothelial cell. Nihon Rinsho Meneki Gakkai Kaishi. 1998; 21(5): 191-7.
  80. Roussev R.G., Stern J.J., Kaider B.D. Anti-endothelial cell antibodies: another cause for pregnancy loss? Am. J. Reprod. Immunol. 1998; 39(2): 89-95.
  81. Savage C.O.S. Endothelial cell antibodies: pathogenetic or epiphenomenon? Nephrol. Dial. Transplant. 1994; 9(10): 1362-3.
  82. Sun Q., Liu Z., Chen J., Chen H., Wen J., Cheng D. et al. Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection. Clin. J. Am. Soc. Nephrol. 2008; 3(5): 1479-86.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2013

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies